Lucid Diligence Brief - BioPharma

SERB–Hansa Idefirix Deal | Lucid Diligence Brief

SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…


Cardiovascular

Cardiovascular Weekly News - May 8th 2025

Cutting-Edge Cardiovascular Breakthroughs You Need to Know! 🧬 From AI-powered…


Privacy Preference Center